Understanding the natural history of olfactory neuroblastoma in patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather comprehensive data on olfactory neuroblastoma (ONB), a rare cancer affecting the nasal cavity. Researchers will evaluate the disease's progression, tumor characteristics, treatment responses, and management strategies through medical history reviews, blood samples, and surveys assessing patients' emotional and physical well-being. Participants will also undergo smell tests to assess their olfactory function. The study will collect clinical, epidemiologic, and biological data to enhance understanding and treatment of ONB.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:.
* Subjects with histologically documented olfactory neuroblastoma.
* Age \>= 3 years old.
* Ability of subject to understand and the willingness to sign a written consent document

EXCLUSION CRITERIA:

Pregnant women are excluded from this study because of more than minimal risk activities (imaging studies with contrast, biopsies) pertaining to enrollment.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Charalampos Floudas, M.D. — National Cancer Institute (NCI)
• Study coordinator: Marissa B Mallek, R.N.
• Email: marissa.mallek@nih.gov
• Phone: (240) 760-7498

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy [212Pb]VMT-Alpha-NET for SSTR-positive metastatic or inoperable GI neuroendocrine, pheochromocytoma/paraganglioma, small cell lung, kidney, and head & neck cancers

  This trial will try an experimental targeted alpha-particle drug called [212Pb]VMT-Alpha-NET in adults whose metastatic or inoperable tumors show somatostatin receptor (SSTR) expression.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06479811

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

• Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents

  This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.

  Recruiting Phase 1/2 Fundación de investigación HM · Boadilla del Monte, Madrid · NCT06607692

• Testing chemotherapy effectiveness for olfactory neuroblastoma

  This study is testing two different chemotherapy combinations to see which one works better for people with olfactory neuroblastoma.

  Recruiting Phase 2 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT06255210

• Using 68-Ga DOTATATE PET/MRI to Diagnose and Manage Certain Brain Tumors

  This study is testing if a special type of imaging called 68Ga-DOTATATE PET/MRI can help doctors better diagnose and manage certain brain tumors, especially meningiomas, by telling the difference between tumor recurrence and changes after treatment.

  Recruiting Phase 4 Weill Medical College of Cornell University · New York, New York · NCT04081701

• Zanzalintinib for Recurrent or Metastatic Olfactory Neuroblastoma

  This study tests whether zanzalintinib can help control recurrent or metastatic olfactory neuroblastoma and whether it is safe.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07527169

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.